Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26016838 | 0.86 | RAB9A (0.50) | RAB9ATSHRHPGDNPC1MEN1 | |
| SCHEMBL6613815 | 0.85 | RAB9A (0.59) | RAB9ATSHRNPC1MEN1KMT2A | |
| SCHEMBL16478650 | 0.83 | RAB9A (0.62) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7030047 | 0.82 | RAB9A (0.72) | RAB9ATSHRNPC1MEN1KMT2A | |
| SCHEMBL14784228 | 0.82 | TSHR (0.71) | RAB9ATSHRHPGDNPC1MEN1 | |
| SCHEMBL29251156 | 0.81 | TDP1 (0.67) | RAB9ATSHRNPC1MEN1KMT2A | |
| SCHEMBL15004187 | 0.80 | TSHR (0.69) | RAB9ATSHRNPC1MEN1KMT2A | |
| SCHEMBL5689000 | 0.80 | RAB9A (0.60) | RAB9ATSHRNPC1MEN1KMT2A | |
| SCHEMBL4775518 | 0.79 | RAB9A (0.83) | RAB9ATSHRNPC1MEN1KMT2A | |
| SCHEMBL16472460 | 0.79 | RAB9A (0.52) | RAB9ATSHRHPGDNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289984-A4 | NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | DONG A PHARM CO LTD (KR) | 2004-11-24 | — | — | EP | disclosed |
| US-6689779-B2 | PYRIDINE OR PYRIMIDINE SUBSTITUTED; ANTIBACTERIAL ACTIVITY; LOW TOXICITY | DONG A PHARM. CO., LTD. (KR) | 2004-02-10 | — | — | US | disclosed |
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | DONG A PHARM. CO., LTD. (KR) | 2003-09-04 | — | — | US | disclosed |
| EP-1289984-A1 | NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | Dong A Pharmaceutical Co. Ltd. (KR) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001094342-A1 | NOVEL OXAZOLIDINONE DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF | DONG A PHARM. CO., LTD. (KR) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166620-A1 | Novel oxazolidinone derivatives and a process for the preparation thereof | OXA1L, ODC1, PDCD4 | RAB9A 3208/4885TSHR 3527/4885HPGD 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.